Century Therapeutics 2025 Q1 Earnings Record Net Income Surges 372.8%

Century Therapeutics (IPSC) reported its Q1 2025 earnings on August 14, 2025, showcasing a dramatic turnaround in profitability. The company significantly outperformed expectations with a net income of $76.56 million, a 372.8% increase from a loss of $28.06 million in Q1 2024. Revenue also soared to $109.16 million, driven by strong performance in its collaboration revenue segment. The results reflect a strategic shift toward capital-efficient development and key clinical progress.

Revenue
Century Therapeutics delivered a robust revenue performance in Q1 2025, with collaboration revenue contributing the full $109.16 million in total revenue. This marked a staggering 12,667.7% increase compared to $855,000 in the same period last year, underscoring the company’s ability to monetize key partnerships effectively.

Earnings/Net Income
The company returned to profitability with an EPS of $0.89, compared to a loss of $0.45 per share in Q1 2024. Net income surged to $76.56 million, a 372.8% improvement from a $28.06 million loss the prior year. This represents a significant operational turnaround and sets a new four-year high for Q1 net income.

Price Action
Following the earnings report, Century Therapeutics’ stock price rose 3.77% on the latest trading day and 3.93% during the most recent full trading week. However, it remains down 4.91% month-to-date.

Post-Earnings Price Action Review
The strategy of purchasing Century Therapeutics shares immediately after the Q1 2025 earnings report and holding for 30 days proved highly ineffective, delivering a return of -94.91% over the past three years. This underperformance was 141.38% worse than the benchmark, with a Sharpe ratio of -0.80 and a maximum drawdown of 0%.

CEO Commentary
Dr. Brent Pfeiffenberger, CEO, emphasized Century’s strategic focus on capital-efficient pipeline development. He highlighted ongoing patient dosing in the CALiPSO-1 trial for CNTY-101, IND-enabling studies for CNTY-308, and progress in its non-immune cell program. The CEO expressed confidence in delivering clinical data for CNTY-101 by year-end 2025 and advancing the pipeline under the Allo-Evasion® 5.0 technology.

Guidance
The company expects to report clinical data for CNTY-101 in B-cell-mediated autoimmune diseases by year-end 2025 and plans to initiate clinical studies for CNTY-308 in 2026. Century also anticipates continued development of its non-immune cell programs and has extended its cash runway into Q4 2027.

Additional News
Over the past three weeks from August 14, 2025, the most-discussed news related to the Nasdaq-100 (NDX) included renewed interest in options strategies and tools for backtesting performance. The Options Architect platform introduced a new calculator to help traders evaluate Nasdaq-100 options strategies at critical market moments. While not directly tied to Century Therapeutics, this tool could be relevant for investors tracking NDX-linked performance. There were no significant M&A announcements, C-level changes, or dividend/buyback news from Century Therapeutics during this period.